Can a Kentucky resident get peptides by telehealth?
Kentucky's general telehealth statute, KRS 211.336, provides that a practitioner-patient relationship may commence via telehealth and that an initial in-person meeting is not required unless the provider decides one is medically necessary. KRS 311.5975 requires physicians using telehealth to obtain informed consent and protect confidentiality, and directs the Kentucky Board of Medical Licensure to adopt regulations to prevent telehealth fraud and abuse. Physicians must hold a Kentucky license (Kentucky participates in the Interstate Medical Licensure Compact). The statutes do not bar asynchronous care for non-controlled drugs. The Board of Medical Licensure's current regulations (201 KAR chapter 9) include no telehealth-specific regulation; the prescribing standards there, 201 KAR 9:260 and 9:270, cover controlled substances and buprenorphine only. Kentucky's medical rules therefore do not address whether a first non-controlled prescription may follow an asynchronous-only intake, so async_prescribing_allowed is left unknown. [2] [5] [6] [9] [15]
How does the Kentucky pharmacy board treat compounding?
| Board | Kentucky Board of Pharmacy |
|---|---|
| Eligible substances | Follows the federal 503A framework |
The Kentucky Board of Pharmacy regulates pharmacies under KRS chapter 315 and Title 201, chapter 2 of the Kentucky Administrative Regulations. Kentucky follows the federal 503A framework for which bulk substances may be compounded, and 201 KAR 2:076 (compounding) incorporates the federal essentially-a-copy limit into state law by prohibiting compounding of essential copies of a commercially available drug product unless authorized by 21 U.S.C. 353a, which the Board says it enforces against every Kentucky licensee and permit holder. Out-of-state pharmacies that ship dispensed drugs to Kentucky patients must hold a Kentucky out-of-state pharmacy permit. KRS 315.0351 requires every pharmacy outside Kentucky that does business in the state, physically or by internet, phone, mail, or other means, to hold an out-of-state pharmacy permit from the Board, disclose its principal officers and dispensing pharmacists annually, keep its home-state license valid, and file its most recent home-state inspection report before applying and each later report after. [1] [3] [4] [7] [10]
Can you get compounded GLP-1s in Kentucky?
The Kentucky Board of Pharmacy's 2025 guidance, "Important Update: Compounding Semaglutide and Tirzepatide," states that in general compounding pharmacies may not compound semaglutide or tirzepatide because they are commercially available, that adding another ingredient such as B12 does not avoid the essentially-a-copy rule, that a lower price is not a valid reason, and that noncompliant compounding may lead to action by both FDA and the Board. The narrow exceptions are a documented patient-specific change that produces a significant difference for that patient, or a return of the drug to the FDA shortage list. [3] [4] [13]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path in Kentucky?
Verified access options
Prescriber licensed in Kentucky, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in Kentucky. Whether questionnaire-only prescribing is permitted is not clearly settled, so expect a live visit.
Pharmacy licensed or registered with the Kentucky Board of Pharmacy
Check the dispensing pharmacy against the board's license lookup before paying, including out-of-state mail-order pharmacies.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Find a provider in Kentucky
Is it legal to buy research peptides in Kentucky?
Only Kentucky-permitted pharmacies may dispense prescription drugs to Kentucky patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and fall outside Kentucky's compounding regulation. The Kentucky Food, Drug and Cosmetic Act, KRS 217.075, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has become effective under the federal act; its investigational exemption covers only drugs intended solely for investigational use by qualified experts and labeled for investigational use only. [1] [8] [14]
Peptide-specific notes for Kentucky
| Peptide | Note |
|---|---|
| Semaglutide | Available branded by prescription, including by telehealth. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies in general may not compound semaglutide, and 201 KAR 2:076 makes the essentially-a-copy prohibition enforceable by the Board; adding B12 does not change that. [3] [4] |
| Tirzepatide | Available branded by prescription. The same Kentucky guidance covers tirzepatide: 503A compounding under the shortage allowance ended in 2025, and compounded copies are allowed only for a documented significant patient-specific difference. [3] [13] |
| BPC-157 | Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. Because it is not commercially available, the essentially-a-copy rule does not apply to it; Kentucky pharmacies apply the federal bulks eligibility test. [4] [11] [12] |
Compare: Semaglutide vs tirzepatide.
Frequently asked questions
Can Kentucky pharmacies compound semaglutide or tirzepatide?
In general, no. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies may not compound semaglutide or tirzepatide because both are commercially available, and 201 KAR 2:076 lets the Board enforce the federal essentially-a-copy ban. The exceptions are a documented patient-specific change that makes a significant difference for that patient, or a return to the FDA shortage list. [3] [4]
Does adding B12 to compounded semaglutide make it legal in Kentucky?
No. The Kentucky Board's guidance repeats FDA's position that a compounded product containing the same active ingredients as commercially available drugs, such as semaglutide plus B12, is still essentially a copy unless the prescriber documents a patient-specific need. [3]
Do I need an in-person visit to get a prescription by telehealth in Kentucky?
Not necessarily. KRS 211.336 allows a practitioner-patient relationship to begin via telehealth, and an in-person meeting is required only if the provider decides it is medically necessary. The prescriber must be licensed in Kentucky. [5] [6]
What does an out-of-state pharmacy need to ship compounded peptides to Kentucky?
A Kentucky out-of-state pharmacy permit from the Kentucky Board of Pharmacy, and any compounded product must still comply with 201 KAR 2:076. Check the Board's license verification before ordering. [1] [4] [7]
Can a Kentucky pharmacy compound BPC-157?
No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [11] [12]
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.
- [1]Kentucky Board of Pharmacy
- [2]Kentucky Board of Medical Licensure
- [3]Kentucky Board of Pharmacy: Important update, compounding semaglutide and tirzepatide (2025)2025
- [4]201 KAR 2:076, Compounding (Kentucky Board of Pharmacy)
- [5]KRS 211.336, Telehealth practitioner-patient relationship
- [6]KRS 311.5975, Duty of treating physician utilizing telehealth
- [7]KRS 315.0351, Out-of-state pharmacy permit (Kentucky Legislative Research Commission)
- [8]KRS 217.075, Restrictions on handling of new drugs (Kentucky Food, Drug and Cosmetic Act)
- [9]201 KAR chapter 9, Kentucky Board of Medical Licensure regulations (Legislative Research Commission index)
- [10]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Are peptides legal in Kentucky?. https://peptideagent.ai/legal/kentucky- HTML link
<a href="https://peptideagent.ai/legal/kentucky">Are peptides legal in Kentucky?</a>, PeptideAgent, updated September 22, 2026.